Dr. Reddy's Laboratories Ltd. NSE: DRREDDY | BSE: 500124

Turnaround Potential

In 4 Starfolio Baskets

Download real time

1273.50 22.70 (1.81%)

1.8M

NSE+BSE Volume

NSE 11 Dec, 2025 3:31 PM (IST)

Enters Agreement

Dr Reddy's enters a $370 mn agreement with Immutep SAS to develop and market Eftilagimod Alfa See details

Dr. Reddy's Laboratories Ltd. share price target

Dr. Reddy's Laboratories Ltd. has an average share price target of 1281.89. The consensus estimate represents an upside of 0.66% from the last price of 1273.50. View 18 reports from 9 analysts offering long-term price targets for Dr. Reddy's Laboratories Ltd..

Reco - This broker has downgraded this stock from it's previous report.
(eg. - Buy->Hold)

Target - Broker has maintained previous recommendation but reduced share price target.

Reco - This broker has upgraded this stock from it's previous report.
(eg. - Sell->Hold)

Target - Broker has maintained previous recommendation but increased share price target.

Load latest Google or static link led you to an intermediate page.

Click on any table column to sort reports by date, stock name, broker, price, target, upside or recommendation.

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report		Discuss
	11 Dec 2025	Dr. Reddy's Labs	Consensus Share Price Target	1273.50	1294.36	-	1.64	hold	pdf Detailed Estimates
	06 Nov 2024	Dr. Reddy's Labs	Prabhudas Lilladhar	1273.50	1335.00	1302.10 (-2.20%)	Target met	Sell	pdf post cache		Broker Report DR REDDY'S LABS Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	06 Nov 2024	Dr. Reddy's Labs	BOB Capital Markets Ltd.	1273.50	1427.00	1302.10 (-2.20%)		Hold	pdf post cache		Broker Report Dr Reddy's Labs (HOLD): Healthy Q2; margins post gRevlimid LOE to remain wary BOB Capital Markets Ltd. Revenue/EBITDA earnings above our and street estimates. APAT ~46% above estimates. Estimates adjusted for JV and impairment cost pdf Copy Link Share on Share on Share on Share on Alert
	06 Nov 2024	Dr. Reddy's Labs	ICICI Securities Limited	1273.50	1270.00	1302.10 (-2.20%)	Target met	Hold	pdf post cache		Broker Report Decent print; work on growth levers underway ICICI Securities Limited Dr. Reddy’s Laboratories’ (DRL) Q2FY25 performance, adjusted for acquisition-related expenses (INR 561mn) and impairment charge of gNuvaring (INR 924mn), was ahead of our expectations pdf Copy Link Share on Share on Share on Share on Alert
	05 Nov 2024	Dr. Reddy's Labs	Motilal Oswal	1273.50	1390.00	1272.20 (0.10%)	Target met	Neutral	pdf post cache		Broker Report North America/Russia/ROW drive earnings Motilal Oswal Dr Reddy’s Lab (DRRD) delivered in-line 2QFY25 performance. DRRD exhibited robust YoY growth in North America (NA), Russia, and ROW markets and a healthy scale-up in the pharmaceutical services and active ingredients segment. pdf Copy Link Share on Share on Share on Share on Alert
	07 Aug 2024	Dr. Reddy's Labs	Geojit BNP Paribas Target	1273.50	7474.00	6926.35 (-81.61%)	Pre-Bonus/ Split	Hold	pdf post cache		Broker Report DR. REDDY'S LABORATARIES Geojit BNP Paribas pdf Copy Link Share on Share on Share on Share on Alert
	30 Jul 2024	Dr. Reddy's Labs	Axis Direct Target	1273.50	7100.00	6804.15 (-81.28%)	Target met	Hold	pdf post cache		Broker Report Result Update:Dr Reddys Labs Axis Direct We have HOLD rating on the stock pdf Copy Link Share on Share on Share on Share on Alert
	29 Jul 2024	Dr. Reddy's Labs	ICICI Direct Reco Target	1273.50	7220.00	6840.05 (-81.38%)	Pre-Bonus/ Split	Hold	pdf post cache		Broker Report Dr Reddy's Laboratories ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	29 Jul 2024	Dr. Reddy's Labs	Prabhudas Lilladhar Target	1273.50	6000.00	6840.05 (-81.38%)	Pre-Bonus/ Split	Sell	pdf post cache		Broker Report DR REDDY'S LABS Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	28 Jul 2024	Dr. Reddy's Labs	ICICI Securities Limited Reco Target	1273.50	6350.00	6878.65 (-81.49%)	Pre-Bonus/ Split	Sell	pdf post cache		Broker Report Surging dependency on gRevlimid ICICI Securities Limited Higher gRevlimid sales, in our view, formed the premise for Dr. Reddy’s Laboratories’ (DRL) Q1FY25 beat. US sales soared 20.3% YoY to USD 462mn riding on market share gains in existing products. pdf Copy Link Share on Share on Share on Share on Alert
	22 May 2024	Dr. Reddy's Labs	Geojit BNP Paribas Target	1273.50	6338.00	5872.75 (-78.32%)	Target met	Hold	pdf post cache		Broker Report DR. REDDY'S LABORATARIES Geojit BNP Paribas pdf Copy Link Share on Share on Share on Share on Alert
more loading

* Please note that subscribers can download a maximum of 300 reports a month and 70 reports everyday.

Advisor Screeners